We are a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. We design, manufacture and market an advanced, next-generation and affordable surgical robotic system called the SSi Mantra Surgical Robotic System (the “SSi Mantra”) intended for use in urology, general, gynecology, colorectal, gastroenterology, head and neck, thoracic and cardiac surgeries. While surgical robotic systems have gained acceptance globally in the past two decades for providing greater efficiency, better clinical outcomes and reducing healthcare costs, access to such systems remains largely limited to developed countries such as the United States (the “U.S.”), the European Union (the “EU”) and Japan. With the SSi Mantra, we are breaking down barriers and accelerating access to surgical robotics technologies in underserved regions of the world.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial
Condition.
The disclosure set forth in
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On August 13, 2026, the Company issued a press
release announcing financial results for the three and six month periods ended June 30, 2026, and the filing with the Securities and Exchange
Commission of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
A copy of the press release is included with this
Current Report as Exhibit 99.1.
The information set forth in Items 2.02 and 7.01 of this Current Report and in the press release included as Exhibit 99.1 to this Current Report, are deemed to be “furnished”
and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section. The information set forth in Items 2.02 and 7.01 of this Current Report and in the press release included as Exhibit 99.1 to this Current Report, shall not be deemed incorporated
by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation
language in such filing.
Forward-Looking Statements
This Current Report and the press release included
as Exhibit 99.1 to this Current Report, includes statements that are not historical facts and are considered forward-looking within
the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical
statements of fact and statements regarding the Company’s intent, belief or expectations, including, but not limited to, statements
regarding the Company’s fourth quarter 2025 and full year 2025 preliminary results, product development, clinical and regulatory
timelines, market opportunity, competitive position, possible or assumed future results of operations and other statements that are predictive
in nature. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,”
“will,” “intend,” “may,” “plan,” “project,” “should,” “could,”
“seek,” “designed,” “potential,” “forecast,” “target,” “objective,”
“goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements
relate to future events or SSi’s future financial performance and involve known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results,
levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance
on forward-looking statements.
Filed exhibits (1)
EX-99.1 (by filename) ea030188701ex99-1.htm
EX-99.1
2
ea030188701ex99-1.htm
PRESS RELEASE, DATED AUGUST 13, 2026
Exhibit 99.1
SS Innovations Reports Second Quarter 2026 Financial
Results
Record quarterly revenue driven by continuing
strong growth in SSi Mantra unit sales
FORT LAUDERDALE, FLA - August 13, 2026
- SS Innovations International, Inc. (the “Company” or “SS
Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable
and accessible to a global population, today announced unaudited financial results for the three and six months ended June 30, 2026. The
Company also filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, with the Securities and Exchange Commission
on August 13, 2026.
Second Quarter 2026 Overview
Revenue increased 39.4% to $13.9 million from
$10.0 million in the second quarter of 2025.
Gross margin equaled 50.9%, compared to 59.1%
in the second quarter of 2025.
Gross profit rose 20.0% to $7.1 million from
$5.9 million in the second quarter of 2025.
Net loss of $2.7 million, or $(0.01) per diluted
share, compared to a net loss of $0.3 million, or $(0.00) per diluted share, in the se…